TOKYO, May 27, 2022 – (JCN Newswire) – – Eisai Co., Ltd. today announced a presentation of research into various types of cancer from its oncology portfolio during 2022 American Society of Clinical Oncology Annual Meeting (# ASCO22), which takes place virtually and in person at Chicago of June 3-7. Notable presentations include a poster discussion of safety and efficacy data (NCT03386942; Abstract: # 5513) from the expansion of a platinum-resistant ovarian cancer cohort in a phase 1 study evaluating an antibody-drug conjugate (ADC) jointly developed by Eisai and Bristol Myers Squibb (headquarters: United States), farletuzumab ekteribulin (MORAb-202), as well as a poster presentation with dose optimization findings for farletuzumab ekteribulin (NCT03386942; Abstract: # 3090).
“Safety and efficacy analyzes in platinum-resistant ovarian cancer for farletuzumab ecteribulin suggest that antibody-drug conjugates may represent a promising therapeutic strategy for these patients with limited treatment options,” said Dr. Takashi Owapresident, Oncology business group in Eisai. “Eisai’s The first antibody-drug conjugate combines our internally developed anti-folate alpha-receptor antibody and our anti-cancer agent eribulin with a cleavable linker enzyme, illustrating our commitment to build on our drugs to improve cancer care for more patients. “
New research from the LEAP clinical program (LEnvatinib And Pembrolizumab) evaluating lenvatinib (LENVIMA) plus pembrolizumab (KEYTRUDA), an anti-PD-1 therapy from Merck & Co., Inc., Rahway, NJ, USA, includes subgroup analyzes from the pivotal phase 3 study CLEAR (Study 307) / KEYNOTE-581 evaluating the combination in patients with advanced renal cell carcinoma (RCC) and the phase 3 study 309 / KEYNOTE-775 evaluating the combination in patients with advanced endometrial cancer ( EC). The poster discussion will evaluate the impact of follow-up therapies in patients with advanced RCC using the combination (NCT02811861; Abstract: # 4514); while the poster presentation will discuss the efficacy of another line of therapy after lenvatinib plus pembrolizumab treatment in advanced EC (NCT03517449; Abstract: # 5587).
“The combination of lenvatinib and pembrolizumab has helped expand physicians’ arsenal of treatment options for patients living with advanced renal cell carcinoma and advanced endometrial carcinoma worldwide,” he said. Richard C. WoodmanMD, Chief Clinical Director, Oncology business group in Eisai. “Our data at ASCO 2022 demonstrate our commitment to continue exploring this combination through post-hoc analysis to provide healthcare professionals with the tools to help them make more informed decisions about their patients’ treatment.”
in March 2018, Eisai and Merck & Co., Inc., Rahway, NJUSA (known externally as MSD United States and Canada), through an associated company, entered into strategic collaboration on the global joint development and joint commercialization of lenvatinib, both as monotherapy and in combination with pembrolizumab. To date, more than 20 studies have been launched under the LEAP clinical program, which evaluates a combination of more than 10 different tumor types.
in June 2021, Eisai and Bristol Myers Squibb have entered into an exclusive global strategic agreement to collaborate on the joint development and joint commercialization of farletuzumab ecteribulin, an folate alpha receptor (FRα) -based ADC. Eisai and Bristol Myers Squibb are currently investigating farletuzumab ecteribulin in FRα-positive solid tumors (including endometrial, ovarian, lung and breast cancer) in two studies: a phase 1 clinical study in Japan and a phase 1/2 clinical study in United States.
This release discusses investigated compounds and research applications for FDA-approved products. It is not intended to communicate conclusions on efficacy and safety. There is no guarantee that any test compounds or trial uses of FDA-approved products will successfully complete clinical development or obtain FDA approval.
For more information, visit www.eisai.com/news/2022/pdf/enews202241pdf.pdf.
public relations department
Eisai Co., Ltd.
+ 81- (0) 3-3817-5120
Copyright 2022 JCN Newswire. All rights reserved.
© Japan Corporate News, source JCN Press Releases